Doctors have conducted a successful trial on a new drug to prevent Acute Respiratory Distress Syndrome (ARDS), which is the cause of most deaths in Corona, to prevent whiteness and stiffness of the lungs. This research was done through the Department of Respiratory Medicine, King George’s Medical University, Lucknow, which has been approved by 25 eminent pulmonologists of the country. He also had an eye on research.
After successful trials on a drug named Aviptavil, the trial report has been sent to the Drug Controller General of India (DCGI) for approval for use in general patients. Researcher doctors say that this drug will protect against ARDS caused by corona as well as other diseases.
Will weaken pneumonia caused by both virus and bacteria. The patient can also be saved from lung fibrosis. Research results have been better. In this, many patients have been saved from the risk of ARDS and many patients have been saved after having ARDS. Different drug interactions have been observed in comorbid patients.
More cases in corona, by the way three patients in two lakh people: ARDS is being reported more due to corona. By the way, under normal circumstances in the country, only three people out of two lakh people have ARDS. More than 50 percent of those who died in Corona were suffering from ARDS.
Once ARDS occurs, it is very difficult to bring patients back to normal. ARDS has been behind most of the deaths in Corona. As of now there is no effective medicine for this, so research is going on different medicines all over the world. In the same episode, the trial of the drug Aviptavil has been very successful. The report has been sent.
– Pro. Suryakant Research Team Leader and Head of the Department of Respiratory Medicine